ATTBF Abattis Bioceuticals Corp

Abattis Announces Resignation of Directors

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.

The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.

About Abattis Bioceuticals Corp.

Abattis is positioned to be a leader in the cannabis industry as a fully integrated medicinal cannabis company. The Company's flagship cultivation asset is located on beautiful British Columbia's Gabriola Island, where the Company plans to grow medical-grade cannabis and select craft strains of infamous "B.C. Bud".

Abattis has also continued to organically grow its products divisions. From its Abattis-branded vaporizer line, to the recent launch of its first proprietary cannabinoid therapeutic formulated for pain, COMFORT™. Abattis also continues to service the cultivation industry through its preferred service agreements with Northern Vine Canada Inc. and Dicentra Inc., one of Canada's largest regulatory advisory firms.

To further its reach into the cannabis space, Abattis has made several strategic investments into cutting-edge research performed in partnership with the University of British Columbia and Mitacs, to research and develop nanoemulsified cannabinoid-rich hemp oil. As well as investments into XLABS Therapeutics (ONT) Inc., building one of Canada's largest cannabinoid manufacturing.

ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,

"Rob Abenante"

Robert Abenante, President & CEO

For more information, please visit the Company's website at:

For inquiries please contact 1 (808) 650-3007 or at . Abattis' investor relations are managed by Canada One Communications Inc.

About Canada One Communications Inc.

Canada One Communications Inc. ("Canada One") is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One's dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.

The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

To view the source version of this press release, please visit

EN
09/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abattis Bioceuticals Corp

 PRESS RELEASE

Abattis and Management Overcome Legal and Regulatory Allegations

Abattis and Management Overcome Legal and Regulatory Allegations After Over Two Years of Legal and Regulatory Battles, Abattis & its Management Receive Vindication VANCOUVER, British Columbia, March 19, 2021 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (“Abattis” or the “Company”) (OTC:ATTBF) is pleased to announce significant progress regarding its dealings with the British Columbia Securities Commission, the Class Action Lawsuit and its Operations. The Securities Commission On November 26, 2018, the British Columbia Securities Commission (the “BCSC”), issued a temporary order (the ...

 PRESS RELEASE

Abattis Provides Update on Trading Halt and Corporate Developments

Abattis Provides Update on Trading Halt and Corporate Developments VANCOUVER, British Columbia, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) announces the following updates on recent developments related to Abattis since the trading of the Company’s common shares on the Canadian Stock Exchange (the “CSE”) was halted on February 4, 2019 (the “Halt”). Regulatory Update  Since the Halt, the Company filed its audited annual financial statements and management discussion and analysis on August 8, 2019. Following this, on Aug...

 PRESS RELEASE

Abattis Announces Successful Closing of Pro Natura Acquisition

Abattis Announces Successful Closing of Pro Natura Acquisition VANCOUVER, British Columbia, May 21, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”). Company Newsletter Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), whic...

 PRESS RELEASE

Abattis Announces Resignation of Directors

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be a leader in the cannabis industry as a fully integrated medicinal cannabis company. The Company's flagship cul...

 PRESS RELEASE

Abattis Provides Update on Conference Call

Abattis Provides Update on Conference Call VANCOUVER, British Columbia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Update on Trading Halt Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year e...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch